If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Strattera Summary of Product Characteristics (SmPC)
Atomoxetine is not a psychostimulant and is not an amphetamine derivative
a randomised, double-blind, placebo-controlled, abuse-potential study
in adults comparing effects of atomoxetine and placebo, atomoxetine
was not associated with a pattern of response that suggested
stimulant or euphoriantproperties.
is a highly selective and potent inhibitor of the pre-synaptic
noradrenaline transporter, its presumed mechanism of action, without
directly affecting the serotonin or dopamine transporters.
Atomoxetine has minimal affinity for other noradrenergic receptors or
for other neurotransmitter transporters or receptors. Atomoxetine has
two major oxidative metabolites: 4-hydroxyatomoxetine and
is equipotent to atomoxetine as an inhibitor of the noradrenaline
transporter but, unlike atomoxetine, this metabolite also exerts some
inhibitory activity at the serotonin transporter. However, any
effect on this transporter is likely to be minimal, as the majority
of 4-hydroxyatomoxetine is further metabolised such that it
circulates in plasma at much lower concentrations (1% of atomoxetine
concentration in extensive metabolisers and 0.1% of atomoxetine
concentration in poor metabolisers).
has substantially less pharmacological activity compared with
atomoxetine. It circulates in plasma at lower concentrations in
extensive metabolisers and at comparable concentrations to the parent
drug in poor metabolisers at steady-state.
Summary of Product Characteristics
Date of Last Review:November 02, 2018
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com